Loading
A South Korean genetic testing company that sells ai-CANCERCH, a blood test for several cancers based on DNA fragment patterns.
GC Genome launched ai-CANCERCH in September 2023 for six cancers, built on whole-genome fragmentomics developed with KAIST (Nature Communications 2023), and announced in November 2025 a planned expansion to ten.
GC Genome's blood test from South Korea, launched in 2023 for six cancers, built on a method published with KAIST.
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/